FLT
FLT (Fms-like tyrosine kinase) inhibitors are compounds that target FLT receptors, which are involved in the regulation of angiogenesis through the VEGF (vascular endothelial growth factor) pathway. FLT receptors play a crucial role in the development of new blood vessels in tumors. Inhibiting FLT receptors can effectively reduce angiogenesis and tumor growth, making these inhibitors important in cancer therapy. At CymitQuimica, we offer a selection of high-quality FLT inhibitors to support your research in oncology, vascular biology, and angiogenesis.
Found 92 products of "FLT"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Formula:C26H34N6O3SPurity:98.82% - 99.81%Color and Shape:SolidMolecular weight:510.65FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Formula:C23H25N5O3Color and Shape:SolidMolecular weight:419.48JNJ-47117096 hydrochloride
CAS:<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Formula:C21H23ClN4O2Color and Shape:SolidMolecular weight:398.89FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Formula:C21H23F3N6OColor and Shape:SolidMolecular weight:432.44FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Formula:C22H23ClFN5O2Color and Shape:SolidMolecular weight:443.91PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Formula:C28H41N9OColor and Shape:SolidMolecular weight:519.68FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Formula:C15H12N4SColor and Shape:SolidMolecular weight:280.35MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Formula:C21H23N3OSPurity:98%Color and Shape:SolidMolecular weight:365.49PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Formula:C27H39N9OColor and Shape:SolidMolecular weight:505.66BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Formula:C24H31N5O4SPurity:98%Color and Shape:SolidMolecular weight:485.6PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Formula:C26H39N9Color and Shape:SolidMolecular weight:477.65FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Formula:C20H25F3N6OColor and Shape:SolidMolecular weight:422.45HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Formula:C23H23N3O3Color and Shape:SolidMolecular weight:389.45FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Formula:C23H26F3N7O2Color and Shape:SolidMolecular weight:489.49KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Formula:C17H17N3O4Color and Shape:SolidMolecular weight:327.33Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Formula:C29H44N8O3C4H4O4Purity:99.78%Color and Shape:SolidMolecular weight:610.75AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Formula:C34H41FN6O5Purity:99.20%Color and Shape:SolidMolecular weight:632.72AC710
CAS:<p>AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).</p>Formula:C31H42N6O4Purity:99.67%Color and Shape:SolidMolecular weight:562.7FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Formula:C23H25N7O2Purity:99.9%Color and Shape:SolidMolecular weight:431.49FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Formula:C22H25N9OPurity:97.4%Color and Shape:SolidMolecular weight:431.49AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Formula:C24H34N8O2SColor and Shape:SolidMolecular weight:498.64LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Formula:C27H42N4O2Purity:98%Color and Shape:SolidMolecular weight:454.65FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Formula:C22H26ClN7O2Color and Shape:SolidMolecular weight:455.94GTP-14564
CAS:<p>GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3.</p>Formula:C15H10N2OPurity:99.69%Color and Shape:SolidMolecular weight:234.25TG-89
CAS:<p>TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and</p>Formula:C26H34N6O3SPurity:98.68%Color and Shape:SolidMolecular weight:510.65OTS447
CAS:<p>OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .</p>Formula:C27H32ClN3O2Purity:98.78%Color and Shape:SolidMolecular weight:466.02UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Formula:C30H44N6OColor and Shape:SolidMolecular weight:504.71FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Formula:C23H25N7O2Color and Shape:SolidMolecular weight:431.49TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Formula:C19H22Cl2N6OSColor and Shape:SolidMolecular weight:453.39SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Formula:C27H24N4O2Color and Shape:SolidMolecular weight:436.505Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Formula:C19H22N6O2Color and Shape:SolidMolecular weight:366.42TAS05567
CAS:<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Formula:C21H29N9O2Purity:98%Color and Shape:SolidMolecular weight:439.51JNJ-47117096
CAS:<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.425E6201
CAS:<p>E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).</p>Formula:C21H27NO6Color and Shape:SolidMolecular weight:389.44LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formula:C30H29Cl2N7OColor and Shape:SolidMolecular weight:574.5TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.50Multi-kinase inhibitor 4
CAS:<p>Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.</p>Formula:C25H24N6O2Color and Shape:SolidMolecular weight:440.50
